The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells

被引:33
作者
Mueller, SN
Jones, CM
Chen, WS
Kawaoka, Y
Castrucci, MR
Heath, WR
Carbone, FR [1 ]
机构
[1] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia
[2] Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia
[3] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Parkville, Vic 3050, Australia
[4] Univ Queensland, Royal Brisbane Hosp, Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Herston, Qld, Australia
[5] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA
[6] Ist Super Sanita, I-00161 Rome, Italy
关键词
D O I
10.1128/JVI.77.4.2445-2451.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The immune response to cutaneous herpes simplex virus type I (HSV-1) infection begins with remarkable rapidity. Activation of specific cytotoxic T lymphocytes (CTL) begins within hours of infection, even though the response within the draining lymph nodes peaks nearly 5 days later. HSV gene products are classified into three main groups, alpha, beta, and gamma, based on their kinetics and requirements for expression. In C57BL/6 mice, the immunodominant epitope from HSV is derived from glycoprotein B (gB(498-505)). While gB is considered a gamma or "late" gene product, previous reports have indicated that some level of gene expression may occur soon after infection. Using brefeldin A as a specific inhibitor of viral antigen presentation to major histocompatibility complex class I-restricted CTL, we have formally addressed the timing of gB peptide expression in an immunologically relevant manner following infection. Presentation of gB peptide detected by T-cell activation was first observed within 2 h of infection. Comparison with another viral epitope expressed early during infection, HSV-1 ribonucleotide reductase, demonstrated that gB is presented with the same kinetics as this classical early-gene product. Moreover, this rapidity of gB expression was further illustrated via rapid priming of naive transgenic CD8(+) T cells in vivo after HSV-1 infection of mice. These results establish that gB is expressed rapidly following HSV-1 infection, at levels capable of effectively stimulating CD8(+) T cells.
引用
收藏
页码:2445 / 2451
页数:7
相关论文
共 55 条
[1]  
Anton LC, 1997, J IMMUNOL, V158, P2535
[2]  
Bachmann MF, 1999, EUR J IMMUNOL, V29, P291, DOI 10.1002/(SICI)1521-4141(199901)29:01<291::AID-IMMU291>3.0.CO
[3]  
2-K
[4]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[5]   Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity [J].
Blaney, JE ;
Nobusawa, E ;
Brehm, MA ;
Bonneau, RH ;
Mylin, LM ;
Fu, TM ;
Kawaoka, Y ;
Tevethia, SS .
JOURNAL OF VIROLOGY, 1998, 72 (12) :9567-9574
[6]   IN-VIVO PRIMING AND ACTIVATION OF MEMORY CYTOTOXIC T-LYMPHOCYTES (CTL) BY A CHIMERIC SIMIAN VIRUS-40-T ANTIGEN EXPRESSING AN 8 AMINO-ACID RESIDUE HERPES-SIMPLEX VIRUS GB CTL EPITOPE [J].
BONNEAU, RH ;
FU, TM ;
TEVETHIA, SS .
VIROLOGY, 1993, 197 (02) :782-787
[7]   Cross-presentation: A general mechanism for CTL immunity and tolerance [J].
Carbone, FR ;
Kurts, C ;
Bennett, SRM ;
Miller, JFAP ;
Heath, WR .
IMMUNOLOGY TODAY, 1998, 19 (08) :368-373
[8]   PROTECTION AGAINST LETHAL LYMPHOCYTIC CHORIOMENINGITIS VIRUS (LCMV) INFECTION BY IMMUNIZATION OF MICE WITH AN INFLUENZA-VIRUS CONTAINING AN LCMV EPITOPE RECOGNIZED BY CYTOTOXIC T-LYMPHOCYTES [J].
CASTRUCCI, MR ;
HOU, S ;
DOHERTY, PC ;
KAWAOKA, Y .
JOURNAL OF VIROLOGY, 1994, 68 (06) :3486-3490
[9]   Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses [J].
Chen, WS ;
Antón, LC ;
Bennink, JR ;
Yewdell, JW .
IMMUNITY, 2000, 12 (01) :83-93
[10]   PATHOGENESIS OF HERPETIC NEURITIS AND GANGLIONITIS IN MICE - EVIDENCE FOR INTRA-AXONAL TRANSPORT OF INFECTION [J].
COOK, ML ;
STEVENS, JG .
INFECTION AND IMMUNITY, 1973, 7 (02) :272-288